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Abstract
Background: Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the
development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR)
and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response.
Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs.
Methodology/Principal Findings: We investigated the relationship between mutations, CNGs and response to TKIs in a
large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were
detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH)
and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were
determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or
either (65/77, 84.4%) were frequent in NSCLC lines. Mutations of EGFR (13%) and KRAS (24.7%) were frequent, while they
were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were
used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were
largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific
imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to
gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results:
1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance.
2. mKRAS was associated with increased in vitro resistance to gefitinib.
Conclusions/Significance: Our in vitro studies confirm and extend clinical observations and demonstrate the relative
importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.
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Introduction
Lung cancer is the leading cause of all cancer deaths worldwide
[1]. Despite the recent advances in diagnosis and multimodality
therapies for lung cancers, the prognosis still remains poor with 5-
year survival rates of only 16% for all stages [2].
Lung cancer is characterized by the accumulation of multiple
genetic and epigenetic alterations including somatic mutations and
gene copy number gains or both which results in the activation of
oncogenes or inactivation of tumor suppressor genes [3].
Epidermal growth factor receptor (EGFR) deregulation has been
observed in multiple tumor types including non-small cell lung
cancers (NSCLCs) [4]. Hirsch et. al. identified frequent EGFR
protein over expression (62%) in NSCLCs of squamous cell and
adenocarcinoma subtypes [5]. EGFR over expression is often
associated with adverse prognosis [6]. The receptor tyrosine kinase
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4576(RTK) super-family of cell surface receptors serves as mediators of
cell signaling by extra-cellular growth factors. Members of the
ERBB family of RTKs including EGFR(HER1/ERBB1), HER2
(ERBB2/EGFR2), HER3 (ERBB3/EGFR3) and HER4 (ERBB4/
EGFR4) have received much attention given their strong
association with malignant proliferation.
The RAS/MAPKand PI3K/AKT pathways aremajorsignaling
networks linking EGFR activation to cell proliferation and survival
[7]. As discussed below, EGFR signaling pathway genes have been
reported to be mutated in NSCLC. Depending on the geographical
location, EGFR and KRAS mutations have been identified in ,10%
230% of NSCLCs [3,8]. EGFR mutations are independently
associated with adenocarcinoma histology, East Asian ethnicity,
never smoking status and female gender. Mutations of KRAS also
target adenocarcinoma histology, but otherwise differ from EGFR
mutations because they are relatively rare in East Asians and occur
more frequently in males and smokers [9]. Less commonly, somatic
mutations have also been found in other EGFR pathway genes
including HER2 (,2%) [10], HER4 (,2%) [11], BRAF (,2%) [12],
and PIK3CA (,4%) [13,14].
Gene copy number gains (CNGs) due to focal amplification or
chromosomal polysomy, is one of the other major mechanisms of
oncogene activation [15]. Lockwood et al. identified multiple
components of the EGFR pathway signaling were frequently
amplified and over-expressed in NSCLC. Interestingly, they also
found that EGFR pathway gene amplification was more frequent
in the adenocarcinoma subtype of NSCLC.
Because of the frequent deregulation of EGFR pathway genes in
NSCLC, EGFR became one of the first rationally selected
molecules for targeted therapy. While initial targeted approaches
utilized monoclonal antibodies which block the ligand-receptor
interaction, newer approaches have utilized small molecule
reversible tyrosine kinase inhibitors (TKIs). The tyrosine kinase
activity of EGFR is required for the biochemical responses induced
bythis receptor[7,16,17].TwoTKIs, gefitinib(Iressa, AstraZeneca)
and erlotinib (Tarceva, Genentech) have been widely used in the
treatment of advanced or recurrent NSCLC. Responses were noted
in subsets, notably East Asian ethnicity, female gender, never
smoking status and adenocarcinoma histology [18,19,20]. Subse-
quently, EGFR mutations were identified in the tyrosine kinase
domain, and predicted for response to TKI in the same subset of
patients [21,22,23]. According to a meta-analysis of 1170 patients,
more than 70% of NSCLCs with EGFR mutations responded to
TKIs, whereas 10% of tumors without EGFR mutation responded
[24]. However, further studies indicated that factors other than
EGFR mutations may play a role in determining response and
survival after TKI therapy. EGFR gene copy number gain was
associated with significantly improved TKI sensitivity and survival
in a large unselected study with appropriate controls [25]. In
addition, other members of the EGFR family i.e. HER2 [26] and
EGFR3 [27] may be important factors involved in TKIsensitivity. A
further complexity is the clinical observation that somatic mutations
of KRAS confer intrinsic resistance to TKIs [28].
To further understand the relationship between TKI sensitivity
and deregulation of EGFR pathway genes, we examined the mutation
and copy number status of seven of these genes (EGFR,HER2,HER3,
HER4, KRAS, BRAF,a n dPIK3CA) in a large panel of lung cancer cell
lines and correlated the data with in vitro sensitivity to TKIs.
Materials and Methods
Tumor Cell Lines
We studied a total of 112 cell lines consisting of 77 NSCLC and
32 small cell lung cancer (SCLC) and three lines from small cell
cancers at extrapulmonary sites (extrapulmonary small cell
cancers, ExPuSC) [29]. All except three of these cell lines were
established by the authors [30] at one of two locations. Cell lines
initiated at the NCI have the prefix NCI-H while lines established
at UT Southwestern have the prefix HCC. NCI-H3255 was
obtained from Dr. Bruce Johnson (Lowe Center for Thoracic
Oncology, Dana-Farber Cancer Institute, Boston, MA) [22]. PC-9
(originally from the Tokyo Medical University, Tokyo, Japan) was
obtained from Dr. Bert Vogelstein (Johns Hopkins University
School of Medicine, Baltimore, MD). Calu-3 was purchased from
American Type Culture Center (Manassas, VA). We also
investigated eight immortalized human bronchial epithelial cell
lines (HBECs, HBEC1KT, HBEC3KT, HBEC4KT, HBEC5KT,
HBEC17KT, HBEC30KT, HBEC31KT and HBEC34KT),
which were initiated by us [31].
Most of the tumor cell lines were maintained in RPMI1640
supplemented with 5–10% fetal bovine serum (FBS). A few cell
lines were grown in ACL4 (for NSCLC lines) and HITES (for
SCLC lines) supplemented with 5% FBS. All HBEC cell lines were
maintained in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) with
bovine pituitary extract (BPE) and recombinant epidermal growth
factor (EGF) [31]. All cell lines were incubated at 37uCi na
humidified atmosphere with 5% CO2.
The genetic fingerprint of each cell line was obtained (Power-
plex 1.2 system, Promega, Madison, WI) and each cell line had a
unique genetic profile which was identical to the profiles obtained
from the American Type Culture Collection.
DNA and RNA extraction
Genomic DNA was obtained from cell line pellets by standard
phenol-chloroform (1:1) extraction followed by ethanol precipita-
tion [32] or by using DNeasy Tissue Kit (QIAGEN, Valencia,
CA). Total RNA was obtained from cell lines using RNeasy Plus
Mini Kit (QIAGEN). cDNA was prepared as described previously
[14].
Gene Sequencing
DNA sequencing and mutational analysis for EGFR (exons 18–
21), HER2 (exons 19 and 20), KRAS (codons 12, 13, and 61), BRAF
(exons 11 and 15) and PIK3CA (exons 9 and 20) were done as
reported by us previously [10,14,32]. HER3 (exons 18–21) and
HER4 (exons18–23) mutation status were analyzed by PCR
amplification of genomic DNA or cDNA and direct sequencing of
the PCR products [10]. The mutations in these genes were
determined using the PCR primers as listed (Table S6). All PCRs
were performed in 25 mL volumes containing 100 ng of DNA
using HotStarTaq DNA polymerase (QIAGEN Inc., Valencia,
CA). DNA was amplified for 32 to 34 cycles at 95uC for
30 seconds, 62uCt o6 8 uC for 30 seconds, and 72uC for
30 seconds followed by 7 minutes extension at 72uC. All PCR
products were incubated using exonuclease I and shrimp alkaline
phosphatase (Amersham Biosciences Co., Piscataway, NJ) and
sequenced directly using Applied Biosystems PRISM dye termi-
nator cycle sequencing method (Perkin-Elmer Co., Foster City,
CA). All mutations were confirmed by independent sequencing in
both directions.
Copy number evaluation
Copy number gains can be evaluated by a number of
methodologies. For clinical samples, fluorescence in situ hybrid-
ization (FISH) is frequently used as it can discriminate between
tumor and non-malignant cells. Laboratory studies of tumor cell
lines (which are free of non-malignant cells) often utilize
quantitative PCR (qPCR). An alternative method is array
EGFR Pathway in Lung Cancer
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comparisons of these methods have seldom been reported [33],
we utilized all three methods.
Real-time qPCR
Gene copy numbers were determined using real-time quanti-
tative PCR employing the Chromo4 PCR System (Bio-Rad
Laboratories, Hercules, CA). To determine the copy number of a
target gene, we used control genes located on the same
chromosome as the target gene (Table S6). The resultant ratios
were compared to similar ratios from diploid cells (the mean values
of the eight HBEC cell lines. TaqMan methodology was used
except for PIK3CA [14]. Primers and probes were chosen by
TaqMan Primer Express
TM 1.5 (Applied Biosystem, Foster City,
CA). Primers were purchased from Invitrogen and probes from
Biosearch Technologies (Novato, CA). The sequences of primers
and probes are shown in Table S6. Standard curves were
constructed with serial dilutions of specific PCR products.
Amplification mixes (25 ml) contained the sample DNA (20 ng),
106 TaqMan buffer (2.5 ml), 200 mM dNTP, 1.25 U Hotstar
Taq
TM DNA polymerase, 200 nM each primer and 100 nM
probe. The thermal cycling conditions comprised 5 min at 95uC
and 40 cycles at 95uC for 15 s and 60uC for 30 s. All the samples
were analyzed in triplicate. The parameter Ct is defined as the
fractional cycle number at which the fluorescence generated by
cleavage of the probe passes a fixed threshold above baseline. The
target gene copy number in unknown samples is quantified by
measuring Ct values and by using a standard curve to determine
the copy number [34]. Gene copy number was calculated using
the following equation: g=(ST/SC)/(NT/NC). PIK3CA copy
number was assessed as described by us previously [14].
Tiling path aCGH
aCGH was performed as previously described [14,15].
Genomic imbalances were identified using aCGH-Smooth [35]
as previously described [36].
FISH assays
Dual-color FISH assays were performed according to a standard
protocol [37,38]. The probe sets, EGFR/CEP7 and PathVysion
and the controls CEP7 were obtained from Abbott Molecular (Des
Plaines, Illinois), HER3/CEP12 was obtained from QBiogene;
BRAF probe was generated from the bacterial artificial clone (BAC)
clone used for aCGH. The copy numbers of the target genes
(labeled in red fluorophores) and the CEP probes (labeled in
Spectrum Green) were verified in at least 100 interphase cells and
20 metaphase spreads. Images were captured and merged using the
CytoVision workstation (Applied Imaging, San Jose, CA).
Sub-cloning
Genomic DNA was isolated from mutant EGFR or KRAS
NSCLC cell lines and used as a template for PCR amplification of
EGFR or KRAS. The primers and the conditions of PCR reactions
were as described previously. PCR products were cloned into
pCR2.1-TOPO vector using TOPO TA cloning kit (Invitrogen).
About 20 clones (range15–25) were selected for sequencing using
either M13 forward primer or corresponding EGFR or KRAS
primers. The results are expressed as the percentages of mutant
alleles present in the total number cloned.
TKI sensitivity
The MTS colorimetric assay (Promega) was performed as per
the manufacturer’s instructions. This assay is based on the
conversion of MTS into soluble formazan by endogenous
dehydrogenase enzymes found in metabolically active cells. Cells
were plated at 1610
3–4610
3 cells/well in tissue culture treated
96-well plates. The following day, TKI (gefitinib or erlotinib) was
added to each plate in a dilution series across the plate such that
eight different concentrations of the drug were tested. On day 5,
20 ml of MTS was added, followed by a 1 hour incubation at 37uC
and then the absorbance was read at 490 nm on a plate reader.
96-well plate data were imported into an in-house Database of
In VItro drug Sensitivity Assays (DIVISA by Luc Girard,
manuscript in preparation) where IC50s are calculated as well as
various statistical analyses. To calculate IC50 values, the data were
background-subtracted (columns 1 and 12 typically contained
media with no cells or drugs and served as background values),
and fitted to the DRC model (R package ‘drc’ by Christian Ritz
and Jens Streibig, http://www.bioassay.dk) to generate a sigmoi-
dal curve from which the concentration that inhibits 50% of the
cells (IC50) was determined.
Statistical Analyses
Fisher’s two-tailed exact tests were determined using the Prism 4
software (Graph Pad, San Diego, CA). P values,0.05 were
considered significant. Other statistical analyses are discussed
under appropriate categories in the Results section.
Results
Mutations (m) and CNGs (g) in lung cancer cell lines
We examined 32 SCLC and three lines from small cell cancers
from extrapulmonary sites (extrapulmonary small cell cancers,
ExPuSC), for somatic mutations and CNGs of EGFR pathway
genes. We found a total of only three mutations in 35 cell lines and
all three were PIK3CA mutations (Table S1). CNGs for EGFR
pathway genes were infrequently encountered in SCLC (Table
S2). Since somatic mutations and CNGs for EGFR pathway genes
were rare in SCLC, we limited our further studies to NSCLC.
For any of the seven genes tested, mutations (39/77, 50.6%),
copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were
frequent in NSCLC lines. These findings are discussed in greater
detail below.
Mutations (m) of EGFR pathway genes in NSCLC
We examined the NSCLC lines, for somatic mutations of EGFR
pathway genes as listed in the Methods section. We found a total of
40 mutations in 39 (50.6%) cell lines (Fig 1a, Table S3). These
mutations consisted of 19 KRAS (24.7%), 10 EGFR (13%), five
BRAF (6.5%), four PIK3CA (5.2%), one HER2 (1.3%), one HER4
(2.2%) and none for HER3.m EGFR,m BRAF and mHER2 were
present exclusively in adenocarcinomas while mKRAS were more
frequent in adenocarcinoma and large cell histologies. mPIK3CA
were the only mutations that did not target adenocarcinoma
histology (Fig. 1c).
Mutations are mutually exclusive
We examined for any association between somatic mutations in
individual cell lines. In order to test the hypothesis that EGFR
pathway gene mutations are mutually exclusive, we used Monte
Carlo simulations to calculate the empirical p-value. The null
hypothesis is that mutations will occur independently. We
simulated the joint distribution of mutation events among these
seven genes using the observed marginal mutation rates and the
independent assumption. In each simulation, we noted the
number of cell lines with multiple mutations. We repeated the
simulations 10,000 times and obtained the empirical distribution
EGFR Pathway in Lung Cancer
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compared the observed number of cell lines with multiple
mutations with this empirical distribution to calculate the p-value.
For this study, the one-sided p-value is 0.0014; therefore, we
rejected the null hypothesis and concluded that gene mutations are
mutually exclusive events for these genes in NSCLC cell lines, with
one exception (Table 1). Large cell carcinoma line NCI-H460 had
both KRAS and PIK3CA mutations.
Comparison of methods for determining copy number
gains
aCGH, FISH and qPCR were used to test the gene copy
numbers for NSCLC cell lines. There is no clear biological
threshold value for defining the abnormal copy numbers for
NSCLC human cell lines; we selected the threshold values which
could achieve the best positive or negative category agreement
among the three tests. Specifically, we computed the Kappa
statistics [39] between aCGH and qPCR tests over two
dimensional cut-off grids as 2, 2.5, 3, 3.5, 4, 4.5 and 5; and then
did the same for FISH and qPCR. The cut-off values that
achieved the best agreement among three tests were as follows: 4
for qPCR, 3 for CGH and 4.5 for FISH; and we used these values
to define the presence of copy number gains in NSCLC cell lines.
Using these cut-off values and all available data, there was highly
significant concordance (p,0.001) between the three methods as
shown in Table 2.
EGFR pathway gene CNGs
As the qPCR data were complete for all lines (while subsets were
tested by the other two methods which are more laborious and
expensive), we used qPCR data for all further analyses. Copy
number gains were frequent (.10%) for EGFR, HER2, HER3 and
Figure 1. Mutations (m) and Copy number gains (g) of EGFR pathway genes in NSCLC. Fig 1a. shows the frequency of mutations and copy
number gains of EGFR pathway genes (EGFR, KRAS, BRAF, PIK3CA, HER2, HER3 and HER4). Forty mutations were identified in 39 cell lines. Mutations
and copy number gains were more frequent for EGFR (13%, 40.3%) and KRAS (24.7%, 14.3%) than other gene. CNGs for HER2 (18.2%) were also
common. We identified only one HER2 and one HER4 somatic mutation. The numbers above the columns indicate the number of cell lines with
mutations (blue columns) or copy number gains (red columns). Fig 1b. The figure depicts the number of genes demonstrating CNGs in mutant and
wild type cell lines. Of the 77 cell lines examined, 39 (50.6%) had a mutation in at least one of seven the EGFR pathway genes examined. CNGs were
frequent in both mutant and wild type cell lines. Fig 1c. shows frequency of mutations on the basis of NSCLC subtype. Mutations of EGFR and BRAF
were exclusively found in adenocarcinoma subtype. The single HER2 mutation was in a adenocarcinoma as compared to the HER4 somatic mutation
which was identified in a squamous cell ca. Fig 1d. shows frequency of copy number gains (CNGs) (g.4 by qPCR) on the basis of NSCLC subtype.
CNGs for BRAF and PIK3CA were seen predominantly in adenocarcinoma and squamous cell carcinoma respectively. CNGs for the rest of the genes
did not favor any subtype.
doi:10.1371/journal.pone.0004576.g001
EGFR Pathway in Lung Cancer
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than twice as frequent (40%) than for any other gene. In general,
with the exceptions of gBRAF (limited to adenocarcinoma
histology), and gPIK3CA (largely limited to squamous cell
histology), CNGs did not show any apparent histology subtype
bias (Fig. 1c).
Relationship between Mutations and Copy number gains
Unlike mutations, copy number gains were not mutually
exclusive either with other CNGs or with mutations (Fig. 2). We
found CNGs for two or more genes in 32.5% (25/77) of cell lines
(Table S4). However, we noted a highly significant association
between mutations of EGFR or KRAS and CNGs of their respective
genes (Fig 3a, 3b).
Mutant allele specific imbalance (MASI) for EGFR and
KRAS genes
As noted above CNGs of EGFR and KRAS were more frequent
in cell lines harboring these mutations. Employing the sub-cloning
method previously described, we investigated whether the EGFR
and KRAS genes preferentially demonstrated mutant allele specific
CNGs in cell lines harboring the respective mutations (Fig. 3). The
data, for testing whether mutant alleles are amplified in gene
mutant cell lines are clustered data with binary outcome. Each cell
line is a cluster and the null hypothesis is that the mutation rate is
0.5. Because the number of subclones in each cell line varied, we
used the analysis approach for the clustered binary outcome with
various cluster sizes [40]. In mutant lines, the mutant allele was
almost always in excess compared to the wild type allele, a
phenomenon we have termed MASI. The p-value for EGFR
mutant cell lines was 0.019 and for KRAS mutant cell line was
0.0003 indicating that the mutant alleles were preferentially
dominant in both cases. Most MASI cases were due to increased
copy number of the mutant allele. However, in a minority of cases
MASI was also noted in cells having diploid or near diploid copy
numbers (acquired uniparental disomy). Thus we used the term
MASI as opposed to mutant allele specific gains.
Characteristics of EGFR Mutant Cell Lines
The clinico-pathologic and molecular data for the 10 NSCLC
cell lines which harbor EGFR mutations are summarized in
Table 3. All contained one of the two major mutations in the
kinase domain, either deletions of exon 19 (n=7) or L858R
mutation in exon 21 (n=3). Mutations were exclusively seen in
adenocarcinoma and never smokers or patients with low tobacco
exposure (#10 pack years). One EGFR mutant cell line was
developed in Japan and the remaining nine were developed in
North America. Of the nine developed in North America, only
one was from an individual of Asian ethnicity. In addition, we
identified that EGFR mutations were more common in compar-
atively younger age group (,55 years).
Seven of these cell lines were sensitive to gefitinib. The three
resistant lines had a second mutation: either the T790M resistance
associated mutation in exon 20 (n=2) or a homozygous deletion of
the PTEN gene and absence of its protein [41] (authors’
unpublished observations).
Effects of mutations and copy number gains on
sensitivity to TKIs
To evaluate the effect of mutations and copy number gains on
sensitivity to TKIs, we analyzed the IC50 values of 45 NSCLC cell
lines. Because TKI clinical sensitivity preferentially targets
adenocarcinoma histology, we included 31 adenocarcinomas.
The entire subset included all of the EGFR, HER2 and HER4
mutant cell lines and 12 KRAS and 3 BRAF cell lines. Because
PIK3CA mutations favored non-adenocarcinoma histology only
one PIK3CA mutant cell line was included. Of the entire subset 17
lines were wild type for all genes tested (Table S5).
We found an excellent concordance between the IC50 values
between gefitinib and erlotinib (p,0.0001) (Fig 4, Table S7).
Because our data set for gefitinib sensitivity was more extensive we
elected to utilize the gefitinib data for further analyses.
Fig. 5 illustrates the sensitivity patterns of the tested cell lines.
The in vitro concentration of 1 mM used in tissue culture
correlates to the plasma concentration of gefitinib in patients
treated with the standard dose of gefitinib i.e. 250 mg a day. This
threshold has been used by researchers in the past to distinguish
sensitive from insensitive and/or resistant cell lines [7]. On the
basis of the above-mentioned threshold and the shape of the curve,
we divided our cell lines into 3 categories: sensitive (#1 mM),
intermediate (.1 mM but #10 mM) and resistant (.10 mM) as
seen in figure Fig. 5. The IC50 values follow a line that
demonstrated a slope change point at approximately 10 mM,
and thus demonstrated an apparently bimodal distribution (Fig. 5).
As cell lines with values below 1 mM were regarded as sensitive, we
arbitrarily categorized values between 1 and 10 mM as being
intermediate in sensitivity.
Table 1. Are mutations of EGFR pathway genes mutually
exclusive?
WT mEGFR mKRAS mPIK3CA mBRAF mHER2 mHER4
WT 38 00 0 0 0 0
mEGFR 0 10 00 000
mKRAS 00 18 1 000
mPIK3CA 00 13 000
mBRAF 00 0 0 5 00
mHER2 00 0 0 0 1 0
mHER4 0 0 00 001
Table 1 shows that mutations of EGFR pathway genes are mutually exclusive in
NSCLC (p,0.05). The only exception was a cell line which harbored mutations
for both KRAS and PIK3CA mutations.
doi:10.1371/journal.pone.0004576.t001









qPCR vs aCGH 317 89.3 ,0.001
qPCR vs FISH 99 71.7 ,0.001
aCGH vs FISH 72 76.4 ,0.001
Gene copy number was measured using three methods, qPCR, aCGH and FISH.
All samples used in this study had qPCR data and subset data for the other two
methods. All available data were pooled and used for analysis of concordance
and kappa statistics. All three comparisons show high concordance with low p
values. Kappa analyses were used to determine the optimal cut-off value for
each test. These analyses yielded the following cut-off values for determining
copy number gains: qPCR$4.0, aCGH$3.0 and for FISH$4.5. Using these cut-
off values, samples were scored as positive or negative for copy number gains
for each type of test, and Fishers two sided tests were used for comparisons of
the different tests.
doi:10.1371/journal.pone.0004576.t002
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included seven of the ten mEGFR lines, one gEGFR cell line and
one gHER2 cell line. The intermediate category consisted of only
two cell lines; a mEGFR cell line having a secondary T790M
mutation and a gHER2 cell line. The resistant cell line category
was the largest and included two mEGFR cell lines, one having the
secondary T790M mutation and the other having homozygous
deletion of PTEN gene. The remaining resistant lines included all
of the wild type lines and all lines having KRAS, BRAF, HER2,
HER4 and PIK3CA mutations.
Using univariate tests, we analyzed the association between
gefitinib sensitivity and mutational status or CNGs of the various
EGFR pathway genes and found a significant correlation between
gefitinib sensitivity with EGFR mutation (p=0.002) and EGFR
copy number gains (p=0.001). We tested the hypothesis that
KRAS mutations confer intrinsic resistance to TKIs. Because
mEGFR was associated with sensitivity to TKIs we excluded these
lines from our analyses. We compared the rank order of IC50s of
mKRAS cell lines with a) all other cell lines and b) cell lines wild
type for all other tested genes. Our univariate analyses
demonstrated that indeed KRAS mutations conferred in vitro
resistance to gefitinib (Table 5). None of the other gene mutations
or copy number gains showed any significant correlation with
gefitinib sensitivity.
We then used a multivariate linear regression model [42] to
explore the association between gefitinib sensitivity and EGFR
mutation, EGFR copy number and HER2 copy number (Table 4).
The response variable was log IC50 values of gefitinib (as a
continuous variable), the predictors are EGFR mutation status
(mutation or wild type EGFR), EGFR copy number (measured by
qPCR) and HER2 copy number (measured by qPCR) as
continuous variables. After adjusting for the effects of EGFR and
HER2 copy numbers, the EGFR mutation status was significantly
associated with the gefitinib sensitivity (p,0.001). Similarly after
adjusting for the effects of the other two variables, the EGFR copy
number (p value=0.002) and HER2 copy number (p=0.021)
were independently and significantly associated with the gefitinib
sensitivity. To summarize the multivariate analysis, all 3
parameters, i.e. mEGFR mutations, gEGFR and gHER2, showed
a correlation with TKI sensitivity in decreasing order of
Figure 2. Copy number gains are not mutually exclusive with either other copy number gains or with mutations. Fig 2a. shows that
copy number gains and mutations are not mutually exclusive. As evident from the figure CNGs for EGFR and KRAS are significantly more frequent in
EGFR and KRAS mutant cell lines respectively (p,0.05). There was only one HER2 and HER4 mutant NSCLC cell line and thus they were not included in
this figure. Fig 2b. shows that copy number gains are not mutually exclusive and gains of one gene may occur in the presence of gains for other
genes.
doi:10.1371/journal.pone.0004576.g002
EGFR Pathway in Lung Cancer
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of EGFR and HER2 as binary variables. In these analyses, EGFR
copy number remained significantly associated with gefitinib
sensitivity (p value,0.001) while HER2 copy number was no
longer significantly associated (p value.0.05; Table 4).
Discussion
In order to clarify some of the conflicting data from clinical
studies, we performed an in vitro study of deregulation of the
EGFR signaling pathway in a large panel of lung cancer cell lines
and correlated the results with TKI sensitivity. In contrast to
SCLC, mutations or CNGs of the studied genes were frequent in
NSCLC – 84.4% of NSCLC cell lines had a mutation, one or
more CNGs or both. Thus the EGFR pathway is deregulated at
high frequency in NSCLC.
Somatic mutations or CNGs of the studied genes were rare in
SCLC and further studies were limited to NSCLC. About half of
the NSCLC lines had a mutation in one of the genes of the EGFR
pathway. The relative distribution of the mutations of EGFR
pathway genes in established NSCLC cell lines were very similar
to those reported from large clinical studies [3,8,10,12,14,43].
EGFR (13%) and KRAS (24.7%) mutations were more frequently
observed than other gene mutations. We found a single mutation
of HER2 and HER4 and no mutations of EGFR3. Mutations of
BRAF and PIK3CA were intermediate in frequency. In general
mutations were more common in adenocarcinoma subtype and
relatively rare in squamous cell carcinomas except for PIK3CA
which was more common in squamous cell carcinomas, as also
occurs in tumors [14]. Mutations were mutually exclusive except
for a single cell line that had both KRAS and PIK3CA mutations.
We have previously reported that mutations of EGFR, KRAS,
BRAF and HER2 were mutually exclusive in 691 resected NSCLC
tumors indicating that a single activating mutation in the EGFR-
RAS-RAF signaling pathway may be sufficient for the pathogen-
esis of many lung cancers [10,14]. However, the mutational status
of PIK3CA was not mutually exclusive, which is similar to another
recent report [14]. We have postulated that the PIK3CA and EGFR
signaling pathways closely interact but that PI3K signaling
represents a partially independent pathway [14].
Copy number gains are believed to be an important mechanism
for activation of the EGFR pathway genes and the downstream
signaling network. CNGs have been difficult to interpret due to the
differences stemming from the use of different methods. Our
Figure 3. Mutant allele specific imbalance (MASI) for EGFR and KRAS genes. EGFR and KRAS genes preferentially have copy number gains
(CNG) in cell lines harboring the respective mutations (panels a and b). In mutant lines, the mutant allele almost always is in excess compared to the
wild type allele (panels c and d), a phenomenon we have termed MASI. In most MASI cases the mutant allele demonstrates CNGs; however MASI may
also be present in cell lines having a diploid copy number of the oncogene, (acquired uniparental disomy) either uniform (NCI-H460) or
heterogeneous (NCI-H1975).
doi:10.1371/journal.pone.0004576.g003
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for binary values after we used kappa statistics to determine the
optimal cut off values for increased copy numbers. However, the
three methods we compared have their individual advantages and
disadvantages. CNGs result from gene over-representation due to
chromosomal polysomy or focal amplification. FISH, a widely
used technique to assess gene copy number takes can identify gains
due to both mechanisms. On the other hand, not only is it
expensive and time consuming but it analyzes only a small subset
of cells (,100 cells) to assess the copy number, and tandem
segmental duplications may not always be detected. Thus
intratumoral heterogeneity is difficult to assess. Both aCGH and
qPCR analyze DNA from many thousands of cells, but because
they compare values for the test gene against an internal standard
(a reference locus), they can detect focal amplifications more
readily than polysomy. In the case of qPCR, if the amplicon
encompasses the reference locus, then amplification may be
underestimated. In the case of aCGH, the copy number deduced
from the signal ratio can appear lower than those obtained by the
other two techniques, for aCGH measures relative and not
absolute copy number. It does not take into account changes in
ploidy and therefore will dampen ratio shifts for copy number
gains in samples with a high DNA index [33]. Thus, the absolute
copy number for a given chromosome region is best determined by
using a combination of complementary methods [44]. Despite the
shortcomings of each method, we found a high concordance
among the three techniques when using binary values (normal/
increased), similar to findings in a recent comparison [33]. We had
most extensive data for gene copy number generated via qPCR
and used it for all our further analysis.
Sixty seven percent of the NSCLC lines had CNGs for one or
more EGFR pathway genes. CNGs for EGFR (40.3%), HER2
(18.2%) and KRAS (14.3%) were more frequent than the other
genes. BRAF CNGs (13%) were more common in adenocarcinoma
subtype and PIK3CA CNGs (36.4%) were more frequent in
squamous cell carcinoma as compared to the other subtypes.
Other genes did not show subtype bias. Unlike mutations, CNGs
were not mutually exclusive either with other CNGs or with
mutations.
However, CNGs were not completely random. We identified
that EGFR and KRAS CNGs were significantly more frequent in
EGFR and KRAS mutant cell lines respectively. Using subcloning,
we determined that in almost all mutant lines with CNGs, the
mutant allele was in great excess in comparison to the wild type
allele. In some lines with diploid amounts of the mutant gene, the
wild type allele was absent or in minute amounts. This finding for
oncogenes (as compared to tumor suppressor genes) has been
described, particularly in hematologic malignancies [45,46], and
represents a form of acquired uniparental disomy. Taken together,
we term this phenomenon as mutant allele specific imbalance
(MASI). Thus MASI may result from specific amplification of the
mutant allele, or by loss of the wild type gene, or by a combination
of these events. Of interest, wild type KRAS may function as an
Table 3. Characteristics of EGFR Mutant Cell Lines.
Cell Line Subtype Sex Race Age
Pack






PC-9 AD ? EA 42 0 19 Del E746-A750 None 5 0.03 1
HCC0827 AD F W 40 4 19 Del E746-A750 None 34 0.04 3
HCC2279 AD F EA 52 ? 19 Del E746-A750 None 5 0.05 4
H3255 AD F W ? ? 21 L858R None 18 0.09 5
HCC2935 AD M W 39 0 19 Del E746-S752 None 4.4 0.1 6
HCC4006 AD M W 52 0 19 Del E746-A750 None 5.2 0.2 7
HCC4011 AD M W 53 5 21 L858R None 8.8 0.5 8
H820 AD M W 53 ? 19 Del E746-E749 T790M 4 3.0 10
H1650 AD M W 27 10 19 Del E746-A750 PTEN Del 2/2 4 11.7 12
H1975 AD F ? ? ? 21 L858R T790M 2.8 25.0 26
Table 3 shows the clinico-pathologic and molecular data for the 10 NSCLC cell lines, which harbor EGFR mutations. These cell lines are arranged in decreasing order of
gefitinib sensitivity. Mutations were exclusively seen in adenocarcinoma and never smokers or patients with low tobacco exposure (#10 pack years or PY). The primary
activating EGFR mutations in all 10 cases were either deletions of exon 19 (n=7) or L858R mutation in exon 21 (n=3). Three cell lines also had a second mutation, either
T790M resistance associated mutation in exon 20 (n=2) or homozygous deletion of the PTEN gene. Contradictory data are available for the gender for the patient from
whom the PC-9 cell line was originated – the surgeon informed us that the patient was female while the distributing institution states that it was from a male (personal
communication from Dr. Harubumi Kato, Tokyo Medical University, Japan). Cell lines considered resistant to gefitinib (IC50.1 mM) are indicated in red. Rank order is the
sensitivity of cell lines to gefitinib in descending order with 1 being the most sensitive. Abbreviations: EA – East Asian, W – White, PY – pack years, Del – deletion.
doi:10.1371/journal.pone.0004576.t003
Figure 4. Concordance between IC50 values for gefitinib vs
erlotinib. Forty five cell lines were tested for sensitivity to both drugs
and the concordance was excellent (p,0.0001).
doi:10.1371/journal.pone.0004576.g004
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suppressor gene [47]. These results suggest that the combination of
two methods of activating the oncogenes EGFR and KRAS (i.e.
mutation and MASI) may confer a greater growth or survival
Figure 5. Rank Order of NSCLC Cell Line depending on the Iressa IC50. Fig 5. shows a log curve of the gefitinib IC50 values for 45 NSCLC cell
lines. They are classified into three categories on the basis of gefitinib IC50: Sensitive (IC50,1 mM), Intermediate (IC50.1 but ,10 mM) and Resistant
(IC50.10 mM). Of the nine sensitive cell lines, seven of them harbor EGFR mutations, one has CNGs for EGFR and one has CNG for HER2. Of the
remaining EGFR mutant cell lines, two had T790M mutation (one intermediate and one resistant) and one had a homozygous deletion of PTEN
(resistant). KRAS mutant and wild type cell lines were all resistant to gefitinib.
doi:10.1371/journal.pone.0004576.g005
Table 4. Results of Multivariate Regression Analyses.
Variable Estimate* Standard Error p-value
EGFR Mutation 21.50 0.28 ,.0001
EGFR relative copy number 20.07 0.02 0.002
HER2 relative copy number 20.01 0.004 0.021
From the multivariate regression analyses three variables were found to be
independently associated with gefitinib sensitivity and are listed in descending
order of importance. The response variable is the log10(IC50) values of gefitinib.
After adjusting for the effects of EGFR and HER2 copy numbers, the EGFR
mutation status is significantly associated with gefitinib sensitivity as indicated
in the ‘‘Estimate’’ column of the Table. The association coefficient is 21.5, which
means after adjusting for EGFR and HER2 copy number effects, the IC50 for
EGFR wild type cell lines is 32 fold higher that that of EGFR mutation cell lines.
After adjusting for the effects of EGFR mutation and HER2 copy numbers, the
EGFR copy number is significantly associated with gefitinib sensitivity. The
association coefficient is 20.07, which means after adjusting for EGFR mutation
and HER2 copy number effects, the IC50 will decrease 0.85 fold when EGFR
relative copy number increases 1 unit.
After adjusting for the effects of EGFR mutation and EGFR copy numbers, the
HER2 copy number is significantly associated with gefitinib sensitivity. The
association coefficient is 20.01, which means after adjusting for EGFR mutation
and EGFR copy number effects, the IC50 will decrease 0.98 fold when HER2
relative copy number increases 1 unit.
*to the base 10.
doi:10.1371/journal.pone.0004576.t004












KRAS mutant 12 21.5 0.03
Wild type for all genes 17 12
Wilcoxon signed rank one-sided test was used to test the hypothesis that
mKRAS confers intrinsic resistance to TKIs. We compared the median rank order
of gefitinib IC50 values of mKRAS cell lines to all other lines excluding EGFR
mutant lines (Comparison 1) and cell lines wild type for all the other genes
tested (Comparison 2). For both analyses EGFR mutant cell lines were excluded
as they were associated with sensitivity to TKIs.
doi:10.1371/journal.pone.0004576.t005
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findings also indicate that mutations must precede CNGs in cells
harboring both changes. Other evidence for the combination of
mutations and CNGs in tumor cells exists [48,49,50,51], and for
the concept that mutations are the initial event [48,49,50,52,53].
EGFR mutations were exclusively found in adenocarcinoma
histology and in never smokers or individuals with low smoke
exposure (,15 PYR). In addition EGFR mutations were more
common in a comparatively younger age group (,55 years).
EGFR mutations did not demonstrate gender bias. Most mutant
lines were derived from Caucasians, which is not surprising
considering that 90% were established in the USA. In rank order
of sensitivity to gefitinib, nine of the EGFR mutant lines were
represented in the 12 most sensitive lines, in keeping with the
previously discussed importance of mutations in sensitivity to
TKIs.
We found an excellent concordance between the IC50 values
between gefitinib and erlotinib. Depending on the previously
determined in vitro threshold for gefitinib and the bimodal curve
we classified our NSCLC cell lines into 3 categories: sensitive,
intermediate and resistant. We had nine sensitive cell lines which
included seven of the 10 EGFR mutant cell lines, one cell line with
EGFR CNG and one with HER2 CNG. Of the remaining 3 EGFR
mutant cell lines, two had the resistance associated secondary
T790M mutation. The third resistant EGFR mutant line had a
deletion of the PTEN gene, a finding associated with TKI
resistance in other systems [54].
Pao et al demonstrated that mutations in KRAS are associated
with a lack of sensitivity to TKIs [28]. We tested the hypothesis
that KRAS mutations confer intrinsic resistance to TKIs and our
univariate analyses demonstrated that indeed KRAS mutations
conferred in vitro resistance to gefitinib. Thus KRAS mutations are
associated with both clinical and in vitro resistance to gefitinib.
None of the other gene mutations or copy number gains showed
any significant correlation with gefitinib sensitivity. In the clinical
setting, approximately 10–20% of NSCLC patients who do not
harbor identifiable EGFR mutations respond partially to gefitinib.
Evidently EGFR mutations are one of the most important but not
the sole determinant of TKI response.
We evaluated the effect of EGFR mutation, EGFR CNGs and
HER2 CNGs on TKI sensitivity using a multivariate regression
analysis. To summarize the multivariate analysis, all 3 parameters,
i.e. EGFR mutations, EGFR CNG and HER2 CNG, showed a
correlation with the TKI sensitivity (used as a continuous variable)
in decreasing order of importance. Thus three previously
identified factors related to patient response to TKIs are major
factors in the in vitro response. However, the most important
independent factor is the presence of activating EGFR mutations.
Our findings may assist in the prediction of response and the
selection of patients for targeted therapies. Another important
finding was the frequent presence of selective imbalance of the
mutant form (MASI) of oncogenes in tumor cells that harbor
mutations of EGFR and KRAS. While MASI may confer a selective
advantage to the tumor cell, its effect on clinical course or response
to therapy remains to be determined.
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